{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:13:31Z","timestamp":1792620811143,"version":"4.5.0"},"reference-count":7,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:p>The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is a key regulatory signaling system for cellular proliferation, differentiation, and apoptosis. In addition, JAK signaling pathway plays critical roles in orchestrating immune response through its interactions with the cytokine receptors and the transcriptions factors. Several key cytokines use JAK-STAT signaling proteins to transduce intra-cellular signals which are involved in the pathogenesis of autoimmune and inflammatory diseases such as in psoriatic disease (psoriasis, psoriatic arthritis), atopic dermatitis, alopecia areata, vitiligo, rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, Sjogren\u2019s syndrome, and other autoimmune diseases. In recent years, understandings of the molecular mechanisms of JAK-STAT pathway in the inflammatory proliferative cascades of autoimmune diseases has led to the development of JAK inhibitors and has opened a new dimension for the treatment of systemic and cutaneous inflammatory diseases. In this symposium we have provided a broad perspective on the use of Janus kinase inhibitors in cutaneous autoimmune diseases.<\/jats:p>","DOI":"10.25259\/ijdvl_8_2023","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T05:29:03Z","timestamp":1690522143000},"page":"688-690","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["JAK inhibitor: Introduction"],"prefix":"10.25259","volume":"89","author":[{"given":"Siba P.","family":"Raychaudhuri","sequence":"first","affiliation":[{"name":"Department of Dermatology and of Medicine\/Division of Rheumatology, Allergy and Clinical Immunology, School of Medicine, UC Davis, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smriti K.","family":"Raychaudhuri","sequence":"additional","affiliation":[{"name":"Department of Veterans Affairs, VA Sacramento Medical Center, Northern California Health Care, California, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"10.25259\/IJDVL_8_2023\/ref-1","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"10.25259\/IJDVL_8_2023\/ref-2","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.cell.2020.04.052","article-title":"SnapShot: Jak-STAT signaling II","volume":"25;181","author":"Villarino","year":"2020","journal-title":"Cell"},{"key":"10.25259\/IJDVL_8_2023\/ref-3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_8_2023\/ref-4","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/BOR.0000000000000810","article-title":"Janus kinase-signal transducers and activators of transcription cell signaling in spondyloarthritis: Rationale and evidence for JAK inhibition","volume":"33","author":"Raychaudhuri","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"10.25259\/IJDVL_8_2023\/ref-5","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1002\/art.41906","article-title":"A Decade of JAK inhibitors: What have we learned and what may be the future?","volume":"73","author":"Liu","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_8_2023\/ref-6","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1136\/annrheumdis-2016-211046","article-title":"Regulatory role of the JAK STAT kinase signaling system on the IL-23\/IL-17 cytokine axis in psoriatic arthritis","volume":"76","author":"Raychaudhuri","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.25259\/IJDVL_8_2023\/ref-7","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1111\/1756-185X.13732","article-title":"Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo 18 F-FDG PET","volume":"22","author":"Raychaudhuri","year":"2019","journal-title":"Int J Rheum Dis"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/jak-inhibitor-introduction\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/jak-inhibitor-introduction\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:34:01Z","timestamp":1693182841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/jak-inhibitor-introduction\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":7,"alternative-id":["10.25259\/IJDVL_8_2023"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_8_2023","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,10]]},"article-number":"688"}}